Management of symptomatic, untreated chronic lymphocytic leukemia

Yvette L. Kasamon, Ian W. Flinn

Research output: Contribution to journalArticle

Abstract

Fludarabine-based regimens have become an increasingly popular first-line approach for symptomatic patients with chronic lymphocytic leukemia. Compared with chlorambucil, fludarabine alone or in combination with cyclophosphamide or rituximab yields higher response rates, higher complete remission rates, and more durable progression-free survival. Immunotherapy and chemoimmunotherapy also have the potential to increase the depth of remission as assessed by flow cytometry or molecular techniques. An overall survival advantage with any one particular regimen has not yet been demonstrated. Progress with fludarabine-based regimens, monoclonal antibodies, chemoimmunotherapy, and high-dose therapy for previously untreated patients is reviewed. Fluorescent in situ hybridization and immunoglobulin variable heavy-chain sequencing now permit more individualized risk assessment. Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question.

Original languageEnglish (US)
Pages (from-to)143-156
Number of pages14
JournalBlood Reviews
Volume21
Issue number3
DOIs
StatePublished - May 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Chlorambucil
Immunoglobulin Heavy Chains
Fluorescence In Situ Hybridization
Immunotherapy
Cyclophosphamide
Disease-Free Survival
Flow Cytometry
Therapeutics
Monoclonal Antibodies
Survival
fludarabine

Keywords

  • Alemtuzumab
  • Chronic lymphocytic leukemia (CLL)
  • Fludarabine
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Management of symptomatic, untreated chronic lymphocytic leukemia. / Kasamon, Yvette L.; Flinn, Ian W.

In: Blood Reviews, Vol. 21, No. 3, 05.2007, p. 143-156.

Research output: Contribution to journalArticle

Kasamon, Yvette L. ; Flinn, Ian W. / Management of symptomatic, untreated chronic lymphocytic leukemia. In: Blood Reviews. 2007 ; Vol. 21, No. 3. pp. 143-156.
@article{3a99ea4c2a9144e68f1dbbc60dce0aae,
title = "Management of symptomatic, untreated chronic lymphocytic leukemia",
abstract = "Fludarabine-based regimens have become an increasingly popular first-line approach for symptomatic patients with chronic lymphocytic leukemia. Compared with chlorambucil, fludarabine alone or in combination with cyclophosphamide or rituximab yields higher response rates, higher complete remission rates, and more durable progression-free survival. Immunotherapy and chemoimmunotherapy also have the potential to increase the depth of remission as assessed by flow cytometry or molecular techniques. An overall survival advantage with any one particular regimen has not yet been demonstrated. Progress with fludarabine-based regimens, monoclonal antibodies, chemoimmunotherapy, and high-dose therapy for previously untreated patients is reviewed. Fluorescent in situ hybridization and immunoglobulin variable heavy-chain sequencing now permit more individualized risk assessment. Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question.",
keywords = "Alemtuzumab, Chronic lymphocytic leukemia (CLL), Fludarabine, Rituximab",
author = "Kasamon, {Yvette L.} and Flinn, {Ian W.}",
year = "2007",
month = "5",
doi = "10.1016/j.blre.2006.10.001",
language = "English (US)",
volume = "21",
pages = "143--156",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Management of symptomatic, untreated chronic lymphocytic leukemia

AU - Kasamon, Yvette L.

AU - Flinn, Ian W.

PY - 2007/5

Y1 - 2007/5

N2 - Fludarabine-based regimens have become an increasingly popular first-line approach for symptomatic patients with chronic lymphocytic leukemia. Compared with chlorambucil, fludarabine alone or in combination with cyclophosphamide or rituximab yields higher response rates, higher complete remission rates, and more durable progression-free survival. Immunotherapy and chemoimmunotherapy also have the potential to increase the depth of remission as assessed by flow cytometry or molecular techniques. An overall survival advantage with any one particular regimen has not yet been demonstrated. Progress with fludarabine-based regimens, monoclonal antibodies, chemoimmunotherapy, and high-dose therapy for previously untreated patients is reviewed. Fluorescent in situ hybridization and immunoglobulin variable heavy-chain sequencing now permit more individualized risk assessment. Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question.

AB - Fludarabine-based regimens have become an increasingly popular first-line approach for symptomatic patients with chronic lymphocytic leukemia. Compared with chlorambucil, fludarabine alone or in combination with cyclophosphamide or rituximab yields higher response rates, higher complete remission rates, and more durable progression-free survival. Immunotherapy and chemoimmunotherapy also have the potential to increase the depth of remission as assessed by flow cytometry or molecular techniques. An overall survival advantage with any one particular regimen has not yet been demonstrated. Progress with fludarabine-based regimens, monoclonal antibodies, chemoimmunotherapy, and high-dose therapy for previously untreated patients is reviewed. Fluorescent in situ hybridization and immunoglobulin variable heavy-chain sequencing now permit more individualized risk assessment. Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question.

KW - Alemtuzumab

KW - Chronic lymphocytic leukemia (CLL)

KW - Fludarabine

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=34047190281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047190281&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2006.10.001

DO - 10.1016/j.blre.2006.10.001

M3 - Article

C2 - 17097783

AN - SCOPUS:34047190281

VL - 21

SP - 143

EP - 156

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 3

ER -